Biopharma’s 6 Biggest Deals: Were They Worth It?

With Amgen set to drop $10.4 billion on Onyx, investors are wondering how effective super-sized biopharma acquisitions are

    View All  

pills spilling prescription bottle 185 flickr Biopharma's 6 Biggest Deals: Were They Worth It?When Amgen (AMGN) announced its $10.4 billion offer to acquire Onyx Pharmaceuticals (ONXX), the market was buzzing not only about the upside of the union for Amgen, but also about the sheer size of the impending deal. At $10.4 billion, the buyout would be one of the biggest biopharma deals ever.

That fact raises some interesting questions, like what were the biotech industry’s biggest acquisitions? And perhaps more important, did those buyouts pay off for the suitors?

Here’s a look at the five largest deals in the history of biopharma, and how they panned out.


Article printed from InvestorPlace Media, http://investorplace.com/2013/08/did-biopharmas-biggest-ever-deals-pay-off/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.